EDOXABAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EDOXABAN (EDOXABAN).
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
| Metabolism | Minimal metabolism via hydrolysis (mediated by carboxylesterase 1), conjugation, and oxidation via CYP3A4; unchanged drug is the predominant form in plasma. |
| Excretion | Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal. |
| Half-life | Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours. |
| Protein binding | Approximately 87% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 62% under fed conditions; taken with food is recommended to achieve consistent exposure. |
| Onset of Action | Oral: Peak plasma concentrations are achieved within 1-2 hours. Anticoagulant effect (anti-Factor Xa activity) is apparent within 1-2 hours after administration. |
| Duration of Action | Anticoagulant effect persists for approximately 24 hours after discontinuation in patients with normal renal function. Duration is prolonged in renal impairment. |
| Molecular Weight | 548.86 |
60 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | CrCl 15-50 mL/min: 30 mg once daily; CrCl <15 mL/min or dialysis: not recommended |
| Liver impairment | Child-Pugh A or B: no adjustment; Child-Pugh C: not recommended |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established |
| Geriatric use | No dose adjustment required; consider renal function and bleeding risk |
| 1st trimester | Avoid due to risk of hemorrhage; no adequate studies. Use only if benefit outweighs risk. |
| 2nd trimester | Avoid due to risk of hemorrhage; minimal data. Use only if benefit outweighs risk. |
| 3rd trimester | Avoid due to risk of hemorrhage and potential for neonatal bleeding. Use only if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for EDOXABAN (EDOXABAN).
| Placental transfer | Crosses placenta; human data limited but expected due to low molecular weight and protein binding. |
| Breastfeeding | Excreted in human milk at low concentrations; risk of bleeding in infant. Use with caution; consider alternative anticoagulants. |
| Lactation Rating |
■ FDA Black Box Warning
Premature discontinuation of edoxaban increases the risk of thrombotic events. Epidural or spinal hematomas may occur in patients receiving anticoagulants who undergo neuraxial anesthesia or spinal puncture, leading to long-term or permanent paralysis.
| Serious Effects |
Active pathological bleedingHypersensitivity to edoxaban or excipientsSevere renal impairment (CrCl <15 mL/min)Concomitant treatment with other anticoagulants except during transition
| Precautions | Increased risk of bleeding, including major and fatal bleeding, Avoid use in patients with mechanical heart valves or moderate to severe mitral stenosis, Renal impairment: dose reduction for CrCl 15-50 mL/min; not recommended if CrCl <15 mL/min, Patients with low body weight (≤60 kg): dose reduction recommended, Concomitant use with other anticoagulants increases bleeding risk, Neuraxial anesthesia or spinal puncture: monitor for signs of spinal hematoma, Pregnancy and lactation: use only if benefit outweighs risk |
| Food/Dietary | No significant food interactions. Edoxaban can be taken with or without food. Grapefruit and grapefruit juice are not expected to interact. Avoid excessive alcohol consumption as it may increase bleeding risk. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | Edoxaban is a direct factor Xa inhibitor. In animal studies, edoxaban caused fetal toxicity (increased post-implantation loss, fetal malformations) at doses equivalent to human exposures. Limited human data: no adequate well-controlled studies in pregnant women. Based on mechanism of action, may cause fetal hemorrhage and placental abruption. FDA Pregnancy Category C: risk cannot be ruled out. First trimester: potential for teratogenicity unknown; second and third trimesters: risk of fetal bleeding, placental complications. Edoxaban should be used during pregnancy only if potential benefit justifies potential risk to fetus. |
| Fetal Monitoring | Maternal: monitor for signs of bleeding, anemia, and hepatic/renal function. Fetal: fetal ultrasound for growth and anatomy if exposed in first trimester; assess for signs of hemorrhage or placental abruption. Neonatal: monitor for bleeding after delivery. INR not used; anti-factor Xa activity may be measured if needed. |
| Fertility Effects | No dedicated fertility studies in humans. In animal studies, no adverse effects on fertility or reproductive performance seen at exposures up to 2 times human exposure. Clinical significance unknown. |
| Clinical Pearls | Edoxaban is a direct factor Xa inhibitor with once-daily dosing. Avoid use in patients with CrCl > 95 mL/min due to increased risk of ischemic stroke. In patients with CrCl 15-50 mL/min, reduce dose to 30 mg once daily. Not recommended in CrCl < 15 mL/min or on dialysis. Reversal agent is andexanet alfa. Avoid concomitant use with strong P-gp inducers (e.g., rifampin). No routine coagulation monitoring required, but anti-Xa assay calibrated for edoxaban can assess exposure if needed. |
| Patient Advice | Take edoxaban exactly as prescribed, once daily with or without food. · Do not stop taking edoxaban without talking to your doctor, as stopping increases your risk of stroke or blood clots. · If you miss a dose, take it as soon as you remember on the same day. Do not double the dose the next day. · Watch for signs of bleeding: unusual bruising, red/pink urine, black/tarry stools, coughing up blood, or heavy menstrual bleeding. Seek immediate medical help if bleeding is severe or you have a fall or head injury. · Inform your dentist and all healthcare providers that you are taking edoxaban before any surgery or dental procedures. · Tell your doctor about all medications you take, especially other blood thinners, NSAIDs (like ibuprofen), aspirin, or other medicines that increase bleeding risk. · Do not drink alcohol excessively as it may increase the risk of bleeding. · Store edoxaban at room temperature, away from moisture and heat. · If you have kidney problems, your dose may be adjusted. Do not change your dose without consulting your doctor. · Seek emergency care if you have sudden severe headache, vision changes, difficulty speaking, or weakness on one side of the body (signs of stroke). |